ATRC News and Press, AtriCure Inc. From 04/01/19

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that it will present at the Needham & Company’s 18 th Annual Healthcare Conference in New York on Wednesday, April 10...

AtriCure Inc. (ATRC) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Lynn Lewis – Investor Relations Mike Carrel – President and Chief Executive Officer Andy Wade – Senior Vice President and Chief Financial Officer Confer...

AtriCure (NASDAQ: ATRC ) Q4 results ($M): Revenues: 52.9 (+14.8%); U.S.: 43.1 (+19.1%). More news on: AtriCure, Inc., Healthcare stocks news, Earnings news and commentary, Read more ...

AtriCure (NASDAQ: ATRC ): Q4 Non-GAAP EPS of -$0.21 misses by $0.04 ; GAAP EPS of -$0.09 beats by $0.08 . More news on: AtriCure, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

2018 Worldwide revenue of $201.6 million – an increase of 15.4% year over year 2018 U.S. revenue of $162.1 million – an increase of 17.2% year over year 2018 International revenue of $39.5 million – an increase of 8.7% year over year Atri...

ACHC , ADSK , AGO , AIMT , ALRM , ALTR , AMBC , AMC , APPF , AQN , ATRC , BIO , BLDR , CARG , CISN , CSLT , DCO , DDD , DELL , EDIT , EIX , EQH , FTCH , GCAP , GPS , GSBD , HABT , ICUI , JAG , JWN , KTOS , KWR , LYV , MAIN , MAR , MAXR , MTZ , NKTR , N...

Endorsement complements the company’s ongoing commitment to physician education AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatment for atrial fibrillation (Afib) and left atrial appendage management, today announced that The Society of Thoracic Surgeons (S...

cryoSPHERE probe launched in United States, designed exclusively for post-operative pain block AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage management (LAAM), today announced that it has launched the cryoICE ...

Trial will evaluate the safety and effectiveness of AtriCure’s cryoICE ® Ablation System for the treatment of persistent and long-standing persistent atrial fibrillation in open concomitant cardiac surgery AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical...

AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its fourth quarter and full year 2018 financial results on Thursday, February 28, 2019. AtriCure will host ...